呲仑帕奈是什么药？

Perampanel is a new highly selective AMPA receptor antagonist that was first approved in 2012 for the adjuvant treatment of partial seizures (with or without secondary generalized seizures) in patients with epilepsy aged 12 years and older. Today let’s learn more about what kind of medicine it is?

Perampanel is a noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor antagonist. Perampanel is approved as an adjunctive treatment for focal epilepsy with or without secondary generalized epilepsy in patients 12 years of age or older in more than 55 countries, including Australia, North America, Europe, Asia and Russia.

Studies in preclinical epilepsy models and clinical evidence indicate that perampanel has anti-epileptic potential and is well tolerated and effective against primary generalized seizures and other focal seizures, with or without secondary generalization. Furthermore, there is extensive clinical experience with perampanel in real-world patients. Of note, perampanel has not been shown to exacerbate other types of seizures, such as absence or myoclonic seizures.

Perampanel reduces calcium inward currents through AMPA receptors in cortical and subcortical brain regions. Increased glutamate levels are associated with impulsive aggression. This is believed to be mediated by stimulation of glutamatergic receptors in the amygdala, hypothalamus, and periaqueductal gray matter. However, the effects of glutamate on behavior are complex, and studies have shown that blockade of AMPA receptors can both reduce behavioral impulsivity and increase impulsivity. The NMDA antagonist phencyclidine has been shown to increase aggression at low doses but decrease aggression at high doses.

Epilepsy is a chronic non-communicable disease of the brain that affects approximately 50 million people worldwide, making it one of the most common neurological diseases worldwide. On September 29, 2019, the State Food and Drug Administration approved the drug import license for Eisai’s new drug perampanel, which is suitable for the additional treatment of adults and children aged 12 and above with partial seizures of epilepsy (with or without secondary generalized seizures).

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.